MetaCap

Sana Biotechnology Inc. (SANA)

NASDAQ: SANAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.59-0.15 (-8.62%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SANA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$476.42M
EPS (TTM)
-$0.52
52-week range
1.57 – 5.49
Day range
1.57 – 1.75
Volume / Avg
4.45M / 3.30M
Beta
—

52-week range

$1.57$5.49

SANA stock today

Sana Biotechnology (SANA) closed at $1.59 on Nov 20, down 8.62% (-$0.15), versus the S&P 500's 3.70% decline. Shares are 71.0% below their 52-week high of $5.49, set on Dec 4, 2025 and 1.6% above the 52-week low of $1.57, near the bottom of the past year's range. SANA is down 60.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 51.7%.

Sana Biotechnology has posted a net loss over the last twelve months (EPS of -$0.52), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Sana Biotechnology

Company profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Steven D. Harr M.D.
Headquarters
Seattle, WA
Employees
142
IPO year
2021
Website
sana.com

Financial highlights

Full financials

Sana Biotechnology reported a net loss of $244.2 million, compared with a loss of $266.8 million a year earlier. Diluted earnings per share came in at -$0.96.

Sana Biotechnology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-244.17M$-266.76M$-283.25M$-269.48M$-355.93M
EPS (diluted)$-0.96$-1.16$-1.46$-1.43$-2.14

Analyst forecast

Forecast

Consensus (9 analysts)

strong_buy

Avg. price target

$8.57+438.99%

  • Strong buy 2
  • Buy 6
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $13.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.07 vs $-0.18
Surprise
+138.89%

SANA news

All SANA news

Sana Biotechnology peers

Health Care sector
SANA peer companies
CompanyPrice% ChgMarket capCompare
RGNXREGENXBIO Inc.7.16-0.28%$473.44Mvs SANA
DNAGinkgo Bioworks Holdings Inc. Class A7.46-9.02%$483.54Mvs SANA
FENCFennec Pharmaceuticals Inc.13.09-2.68%$462.14Mvs SANA
VALNValneva SE ADR5.16-3.82%$490.86Mvs SANA
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs SANA
IRLAIRulya Therapeutics Inc.39.88-0.15%$432.36Mvs SANA
PROKProKidney Corp. Class A1.04-1.89%$415.21Mvs SANA
TECXTectonic Therapeutic Inc.20.73-1.47%$405.26Mvs SANA

Indexes, lists and sector

Sana Biotechnology stock FAQ

What is Sana Biotechnology's stock price today?

SANA last traded at $1.59 as of Nov 20, 4:00 PM EST, down 8.62% on the day. Prices are delayed at least 15 minutes.

Who is Sana Biotechnology's CEO?

Dr. Steven D. Harr M.D. is the chief executive officer of Sana Biotechnology Inc., which has about 142 employees.

What is the SANA 52-week high?

The 52-week high for SANA is $5.49 and the 52-week low is $1.57. The stock is currently 71.0% below its high.

Compare SANA